Fairmount Funds Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Fairmount Funds Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-953,396	Closed	-$30.5M	–	28
2022 Q2	$30.5M	Sell	953,396 -228,911	-19%	-$6.7M	6.97%	4
2022 Q1	$41M	Buy	1,182,307 +439,307	+59%	+$13.1M	9.68%	2
2021 Q4	$21.7M	Buy	743,000 +493,000	+197%	+$15.3M	7.17%	5
2021 Q3	$6.37M	Buy	250,000 +40,000	+19%	+$1.18M	2.32%	17
2021 Q2	$7.35M	Buy	210,000 +35,000	+20%	+$1.37M	3.02%	16
2021 Q1	$7.13M	Sell	175,000 -40,000	-19%	-$1.84M	3.01%	16
2020 Q4	$9.31M	Buy	+215,000	New	+$10.6M	3.33%	13

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fairmount Funds Management's GBT Position: Q3 2022 in Review

Fairmount Funds Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 953,396 shares — an estimated $30.5M sold.

Fairmount Funds Management first reported a position in GBT in Q4 2020 and held it in 7 quarters. The position peaked at $41M in Q1 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

Fairmount Funds Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Fairmount Funds Management sold 953,396 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $30.5M.
Fairmount Funds Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 7 quarters.
Fairmount Funds Management's Global Blood Therapeutics, Inc. position peaked at $41M in Q1 2022.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Fairmount Funds Management's 13F filing for Q3 2022, filed 9 Nov 2022.